A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

NCT01604889 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
50
Enrollment
INDUSTRY
Sponsor class

Stopped Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued.

Conditions

Interventions

Sponsor

Incyte Corporation